Horizon Techn Stock Price, News & Analysis

Horizon Technology Finance (NASDAQ: HRZN) has provided a $10 million venture loan facility to Finexio, with $5 million initially funded. Finexio, backed by JP Morgan and Mendon Venture Partners, is a B2B payments company offering AI-powered 'Accounts Payable Payments as a Service'. The platform automates and digitizes payments through various methods including ACH, virtual credit cards, and checks, integrating with existing AP and Procurement systems.

The loan proceeds will be used for general growth and working capital purposes. Finexio's platform utilizes predictive analytics to optimize payment timing and cash flow while providing fraud prevention capabilities.

Horizon Technology Finance has provided a $10 million venture loan facility to Ursa Space Systems, a leading satellite intelligence company. Ursa Space serves government and commercial clients worldwide through an extensive virtual network of over 200 satellites, combining Synthetic Aperture Radar, Electro-Optical, and Radio Frequency data with AI-enabled processing. The company, backed by investors including Dorilton Capital, RRE Ventures, and Paladin Capital Group, will use the loan proceeds for general growth and working capital purposes. Ursa Space's platform provides access to over 55 million satellite images and delivers critical intelligence through custom solutions and subscription services.

Horizon Technology Finance (NASDAQ: HRZN) has declared monthly cash distributions of $0.11 per share for January, February, and March 2025, totaling $0.33 per share. Since its 2010 IPO, Horizon has distributed $286 million to shareholders. The company maintains a Dividend Reinvestment Plan (DRIP) allowing automatic reinvestment of distributions into additional shares unless stockholders opt out. DRIP shares can be issued as new stock or purchased from the open market, with valuation based on closing prices or average purchase prices respectively.

Horizon Technology Finance (NASDAQ: HRZN) reported third quarter 2024 financial results with net investment income of $11.8 million ($0.32 per share), down from $17.4 million ($0.53 per share) in Q3 2023. The total investment portfolio reached $684.0 million, with a debt portfolio yield of 15.9%. The company funded nine loans totaling $93.1 million and raised $18.4 million through ATM offerings. Net asset value was $342.5 million ($9.06 per share). The company declared monthly distributions of $0.11 per share through March 2025, with undistributed spillover income of $1.27 per share.

Horizon Technology Finance (NASDAQ: HRZN) reported significant progress in Q3 2024, originating $93.1 million in new loans. The company ended the quarter with a committed backlog of $189.9 million in debt investments. Key highlights include:

- Funded $93.1 million in loans to various companies
- Experienced liquidity events from four portfolio companies, with $37.5 million in principal prepayments
- Received $12.4 million in regularly scheduled principal payments
- Closed new loan commitments totaling $172.9 million to eight companies
- Held a portfolio of warrant and equity positions in 103 portfolio companies

HRZN's President, Gerald A. Michaud, noted the improving venture environment and expressed confidence in the company's position to deliver additional value to shareholders.

Horizon Technology Finance (NASDAQ: HRZN) has provided a $35 million venture loan facility to GT Medical Technologies, Inc. (GT MedTech), with $15 million initially funded. GT MedTech's flagship product, GammaTile®, is a bioresorbable collagen tile embedded with radiation seeds (Cesium-131) for treating brain tumors. This innovative solution delivers targeted radiation directly to the tumor cavity, reducing recurrence and minimizing exposure to healthy tissue.

GT MedTech, backed by investors like MVM Partners and Glide Healthcare Partners, will use the loan for growth and working capital. The FDA-cleared GammaTile aims to transform brain tumor treatment standards while offering a cost-effective reimbursement profile for hospitals.

GT Medical Technologies, Inc. has secured a $35 million venture loan facility from Horizon Technology Finance (NASDAQ: HRZN), with an initial funding of $15 million. The company plans to use the proceeds to execute strategic commercial and clinical expansion plans for GammaTile®, their innovative targeted radiation solution for brain tumors. GammaTile is a bioresorbable collagen tile embedded with Cesium-131 seeds, delivering high-dose radiation directly to tumor cavities while minimizing damage to healthy tissue.

GT MedTech aims to improve access to care and expand GammaTile utilization for patients with high-grade gliomas, brain metastases, and aggressive meningiomas. The company is backed by notable investors, including MVM Partners and Glide Healthcare Partners, and plans to invest more resources into GammaTile's development and expand its commercial teams nationwide.

Vesta Healthcare, a virtual care provider for people with home care, has secured $65 million in Series C funding. The equity round was led by RA Capital Management, with participation from various investors including Oak HC/FT, Chrysalis Ventures, and CareCentrix/Walgreens. Horizon Technology Finance provided debt financing.

Vesta Healthcare serves over 50,000 people, connecting patients, family, caregivers, home care agencies, providers, and insurance plans. Their technology and services span from home-based primary care to passive monitoring, aiming to help people with home care live longer, healthier lives at home.

The company plans to use this funding to propel growth and continue improving healthcare outcomes for those with home care needs.

Horizon Technology Finance (NASDAQ: HRZN) has provided a $35 million venture loan facility to Vesta Healthcare, with $25 million initially funded. Vesta Healthcare is a tech-enabled clinical services company that integrates caregivers, patients, and healthcare systems to monitor chronic conditions of high-risk patients. The company aims to reduce hospital admissions and emergency visits through 24/7 clinical support and advanced analytics, ultimately minimizing unnecessary care utilization and generating cost savings.

Vesta Healthcare is backed by notable investors including RA Capital Management, Oak HC/FT, and Kaiser Permanente Ventures. The loan proceeds will be used for general growth and working capital purposes. This funding supports Vesta's mission to deliver value-based health programs and keep high-risk patients safely in their homes, enhancing their quality of life.